KRT5 and ovarian serous adenocarcinoma: We confirmed in a cohort of advanced stage serous ovarian cancers that patients with high K5/6 or high K5 immunostaining (≥ 10.0%) had a significantly reduced PFS compared to patients with low K5/6 or low K5 positivity (< 10.0%, Figure 4A, 4C).